Reuters logo
BRIEF-Global Blood Therapeutics says EU has designated GBT440 as orphan medicinal product
November 30, 2016 / 2:15 PM / a year ago

BRIEF-Global Blood Therapeutics says EU has designated GBT440 as orphan medicinal product

Nov 30 (Reuters) - Global Blood Therapeutics Inc

* Global Blood Therapeutics says European Commission has designated GBT440 as an orphan medicinal product for treatment of sickle cell disease

* Global Blood Therapeutics says EC acted on a positive recommendation from committee for orphan medicinal products of European medicines agency Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below